Trovagene,Inc. (NASDAQ:TROV) Files An 8-K Other EventsItem 8.01 Other Events.
On August16, 2017, Trovagene,Inc. (the “Company”) issued a press release announcing positive data from a preclinical in-vivo study examining the combination of the Company’s PLK1 inhibitor, PCM-075, with a leading investigational FLT3 inhibitor. A copy of the press release is furnished as Exhibit99.1 to this Form8-K.
Item 9.01. Financial Statements and Exhibits
(d)Exhibits.
|
99.1
|
Press Release of Trovagene,Inc. dated August16, 2017
|
Trovagene, Inc. ExhibitEX-99.1 2 a17-20271_1ex99d1.htm EX-99.1 Exhibit 99.1 Trovagenes PLK1 Inhibitor PCM-075,…To view the full exhibit click here
About Trovagene,Inc. (NASDAQ:TROV)
Trovagene, Inc. (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics. It has ongoing clinical collaborations to demonstrate the ability to determine and monitor mutational status and response to therapy in lung, colon, pancreatic and skin cancer. It uses its molecular diagnostic technology for the detection of cell-free deoxyribonucleic acid (DNA) originating from diseased cell death that can be isolated and detected from urine, blood and tissue samples to develop disease management.